These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 20433955)

  • 21. Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?
    Voll RE; Kalden JR
    Ann N Y Acad Sci; 2005 Jun; 1051():799-810. PubMed ID: 16127017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Rheumatoid arthritis: strategies for biotherapy].
    Nau JY
    Rev Med Suisse; 2012 Oct; 8(358):1988-9. PubMed ID: 23198655
    [No Abstract]   [Full Text] [Related]  

  • 23. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis.
    Tsao NW; Bansback NJ; Shojania K; Marra CA
    Best Pract Res Clin Rheumatol; 2012 Oct; 26(5):659-76. PubMed ID: 23218430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential use of biologic therapy in rheumatoid arthritis.
    Buch MH
    Curr Opin Rheumatol; 2010 May; 22(3):321-9. PubMed ID: 20190641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks?
    Nurmohamed MT
    Drugs; 2009 Oct; 69(15):2035-43. PubMed ID: 19791825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perspectives on rheumatoid arthritis for the orthopedic surgeon: overview of non-tumor necrosis factor biologic drugs and perioperative management.
    Keith MP
    Am J Orthop (Belle Mead NJ); 2011 Dec; 40(12):E272-5. PubMed ID: 22268021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New therapies for treatment of rheumatoid arthritis.
    Smolen JS; Aletaha D; Koeller M; Weisman MH; Emery P
    Lancet; 2007 Dec; 370(9602):1861-74. PubMed ID: 17570481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies.
    Favalli EG; Biggioggero M; Marchesoni A; Meroni PL
    Rheumatology (Oxford); 2014 Sep; 53(9):1664-8. PubMed ID: 24729445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
    Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
    J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biological drug treatment of rheumatoid arthritis and spondyloarthritis: effects on QT interval and QT dispersion.
    DI Franco M; Paradiso M; Ceccarelli F; Scrivo R; Spinelli FR; Iannuccelli C; Valesini G
    J Rheumatol; 2012 Jan; 39(1):41-5. PubMed ID: 22045840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abatacept: new drug. Rheumatoid arthritis: after failure of TNF alpha antagonists and rituximab.
    Prescrire Int; 2008 Dec; 17(98):232. PubMed ID: 19422143
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
    Davies A; Cifaldi MA; Segurado OG; Weisman MH
    J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Paradigm shift in the treatment of rheumatoid arthritis by biologics].
    Tanaka Y
    Rinsho Byori; 2008 Apr; 56(4):309-15. PubMed ID: 18516965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of abatacept in rheumatoid arthritis.
    von Kempis J; Dudler J; Hasler P; Kyburz D; Tyndall A; Zufferey P; Villiger PM
    Swiss Med Wkly; 2012; 142():w13581. PubMed ID: 22581564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.
    Yuan Y; Trivedi D; Maclean R; Rosenblatt L
    J Med Econ; 2010 Mar; 13(1):33-41. PubMed ID: 20001596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New drugs for rheumatoid arthritis.
    Messori A; Santarlasci B; Vaiani M
    N Engl J Med; 2004 Aug; 351(9):937-8. PubMed ID: 15329436
    [No Abstract]   [Full Text] [Related]  

  • 39. The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.
    Navarro Coy NC; Brown S; Bosworth A; Davies CT; Emery P; Everett CC; Fernandez C; Gray JC; Hartley S; Hulme C; Keenan AM; McCabe C; Redmond A; Reynolds C; Scott D; Sharples LD; Pavitt S; Buch MH
    BMC Musculoskelet Disord; 2014 Dec; 15():452. PubMed ID: 25539805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Recent topics on new biological agents for treatment of rheumatoid arthritis].
    Saito K; Tanaka Y
    Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2418-23. PubMed ID: 19149039
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.